Skip to content

Non-Hodgkin's Lymphoma

Font Size

Changes to This Summary (02 / 19 / 2013)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

    General Information About Adult Non-Hodgkin Lymphoma (NHL)

    Recommended Related to Non-Hodgkin's Lymphoma

    Primary Gastric Lymphoma

    Important It is possible that the main title of the report Primary Gastric Lymphoma is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

    Read the Primary Gastric Lymphoma article > >

    Updated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 2).

    Indolent NHL

    Added text to state that follicular lymphoma in situ and primary follicular lymphoma of the duodenum are particularly indolent variants that rarely progress and rarely require therapy (cited Schmatz et al. and Jegalian et al. as references 17 and 18, respectively).

    Revised text to state that myeloablative therapy with autologous or allogeneic hematopoietic stem cell support is under clinical evaluation (cited Kyriakou et al. as reference 48).

    Added Nakamura et al. as reference 62.

    Added Kempf et al. as reference 97.

    Aggressive NHL

    Added Glantz et al. as reference 18.

    Added text to state that similar response rates in relapsing patients were seen for the histone deacetylase inhibitor ramidepsin for 130 evaluable patients in a prospective trial (cited Coiffler et al. as reference 70).

    Added Di Sabatino et al. as reference 87.

    Added Bazarbachi et al. as reference 125.

    Added Griffiths et al. as reference 143.

    Added LaCasce et al. as reference 144.

    Stage Information for Adult NHL

    Revised text to state that interim positive emission tomography (PET) scans after two to four cycles of therapy did not provide reliable prognostic information because of problems of interobserver reproducibility in a large cooperative group trial, ECOG-E3444, and lack of difference in outcome between PET-negative and PET-positive/biopsy-negative patients in two prospective trials (cited Pregno et al. as reference 9).

    Added Salles et al. and Advani et al. as references 13 and 14, respectively.

    Treatment for Indolent, Stage I and Contiguous Stage II Adult NHL

    Added Kelsey et al. and Seymour et al. as references 6 and 7, respectively.

    Treatment for Indolent, Noncontiguous Stage II/III/IV Adult NHL

    Revised text to state that rituximab may be considered as first-line therapy, either alone or in combination with other agents.


      Today on WebMD

      stem cells
      What are they and why do we need them?
      Lung cancer xray
      See it in pictures, plus read the facts.
      sauteed cherry tomatoes
      Fight cancer one plate at a time.
      Ovarian cancer illustration
      Do you know the symptoms?
      Vitamin D
      New Treatments For Non-Hodgkins Lymphoma
      Lifestyle Tips for Depression Slideshow
      Pets Improve Your Health

      WebMD Special Sections